Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

BACKGROUND: Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriate dose for Phase II studies, characterize ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Creelan, Ben C, Gabrilovich, Dmitry I, Gray, Jhanelle E, Williams, Charles C, Tanvetyanon, Tawee, Haura, Eric B, Weber, Jeffrey S, Gibney, Geoffrey T, Markowitz, Joseph, Proksch, Joel W, Reisman, Scott A, McKee, Mark D, Chin, Melanie P, Meyer, Colin J, Antonia, Scott J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587199/
https://www.ncbi.nlm.nih.gov/pubmed/28919776
http://dx.doi.org/10.2147/OTT.S136992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587199/
https://www.ncbi.nlm.nih.gov/pubmed/28919776
http://dx.doi.org/10.2147/OTT.S136992

Ejemplares similares